Through effects on insulin-secreting β cells, EPE increases the release of endogenous insulin via insulin-p-Akt-p-FoxO1 and/or via hepatic p-AMPK to suppress the hepatic PEPCK pathway and improve muscle membrane GLUT4 protein levels, thereby producing hypoglycemia. The gene discussed is AKT1; the disease is Hypoglycemia.